Please provide your email address to receive an email when new articles are posted on . Approximately 1% to 3% of all prescriptions written in the United States are for compounded drugs. Physicians ...

Patricia Louis is a content editor and social media strategist with a strong background in journalism, public relations and business. As the organic social media editor, she oversees and develops ...

FDA proposes excluding blockbuster weight-loss drugs from 503B compounding list Move could limit bulk production by outsourcing facilities Novo and Lilly support FDA stance If finalized, the move ...

Weight-loss company Noom has acquired 503A pharmacy Tailor Made Compounding, which Noom said will allow it to expand its behavior change programs and move beyond weight health. Tailor Made provides ...

Drugmaker Eli Lilly says some copycat versions of its GLP-1 medications pose unique safety concerns — here’s what you need to know. A new study funded by Eli Lilly found that mixing compounded ...

Though it’s hard to say exactly what the future holds for mass GLP-1 compounding, the pressure is mounting from multiple angles in the U.S. as drugmakers and the FDA alike seek to crack down on the ...

Compounded versions of tirzepatide (Mounjaro, Zepbound) containing vitamin B12 pose a potential safety risk to the public, Eli Lilly warned in an open letter on Thursday. Following laboratory testing, ...

The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. In its latest offensive, the agency has unleashed a fresh set of 30 warning letters targeting ...

As GLP-1s remain popular across the U.S., the Food and Drug Administration says it’s now prepared to rein in a fast-growing corner of the market: compounding pharmacies and telehealth companies that ...

FDA enforcement will focus on restricting GLP-1 APIs in mass-marketed, nonapproved compounded products to address unverifiable quality, safety, and efficacy under the FD&C Act. Appropriate compounding ...

Note: Compounded drugs are not approved by the U.S. Food and Drug Administration (FDA) and may carry greater risks than FDA-approved treatments. In April 2025, the U.S. Food and Drug Administration ...

The US Food and Drug Administration (FDA) recently issued warning letters to more than 40 compounding pharmacies, demanding that they cease certain advertising practices for a variety of compounded ...